Manel boumeg.MD

Cardiologist 🇩🇿🇺🇸

[JACC Journals @JACCJournals]

🌟 Big news in #Cardiology! The Coronary Sinus Reducer 💉 improves angina, #QoL, & coronary flow reserve in CMD patients with #ANOCA. A breakthrough for those with limited treatment options! 💓🩺 https://t.co/yNIGP5DwGu

#JACCINT @Mi@Michel_CorbanMD @LermanAmir @adnanalkhouli @claireraph @rajivxgulati @ChetRihal

[Abdullah Al-Abcha @AbdullahAlabcha]

‼️Check out our #JACCINT manuscript demonstrating the #prognostic implications☠️ of #cardiac_damage🫀 in patients with #MAC and mitral valve dysfunction #MVD

https://t.co/TfOpAlOBwe

Tremendously grateful to @MayraGuerreroMD ‘s mentorship🙏🏽

1/n👇🏽

@JACCJournals #CardioTwitter

[American Society of Echocardiography @ASE360]

🫀NEW GUIDELINE🫀 https://t.co/5IgVlfDlnd
We have just released "Guidelines for the Evaluation of Prosthetic Valve Function With Cardiovascular Imaging," in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography!

[Mayra Guerrero, MD @MayraGuerreroMD]

MViV, MViR & ViMAC with Sapien 3 associated with sustained improvement of HF symptoms & QoL @ 5 years. Stable THV function in all groups. MViV had excellent survival @ 5 years, lower survival in MViR & ViMAC. Thank you all collaborators! @MayoClinicCV
https://t.co/CXUrtEalZg

[Abdullah Al-Abcha @AbdullahAlabcha]

#Sustainability♻️ in the #cath_lab🫀

I had the pleasure to talk to Dr. @mirvatalasnag about her viewpoint 📝 in this #JACCINT issue👇🏽

https://t.co/NAHwDbOpgB

@JACCJournals #CardioTwitter #MedTwitter

[Michael J. Blaha @MichaelJBlaha]

I think these SELECT top line results are the most important for preventive cardiology since the JUPITER trial. Incredible implications for our field. https://t.co/eRHDAuByn5

[Mohammed Qintar, MD MSc @MohammedQintar]

70 y/o E. coli bacteremia, WBC >50, on pressors not doing well, showering all over the place. Turned down for surgery. Successfully treated with left sided aspiration with Angiovac device.

[Gregg W. Stone MD @GreggWStone]

I'm pleased to announce that PROTECT IV, our large-scale randomized trial of Impella CP circulatory support vs. control in 1252 pts with low LVEF and extensive CAD undergoing complex PCI has randomized its 626th patient - half-way complete! - a major milestone.

[Manel boumeg.MD @manelboumeg]

Will see… my guess monotherapy will do well #CardioTwitter

[EuroIntervention @EuroInterventio]

The NEOMINDSET trial will investigate whether monotherapy with a potent P2Y12 inhibitor is noninferior to dual antiplatelet therapy (DAPT) with respect to ischemic outcomes and superior to DAPT in reducing bleeding in patients with ACS undergoing PCI. https://t.co/m2e7mQNiZE

[Manel boumeg.MD @manelboumeg]

Impressive outcome ! ZERO all cause death and stroke at one year! #CardioTwitter

[Mayra Guerrero, MD @MayraGuerreroMD]

On behalf of P3 investigators, we share “1-Year Outcomes of PARTNER 3 MViV Intermediate Risk Registry” presented today @ #TVT2023. Primary Endpoint of All-Cause Death or Stroke at 1 year, was ZERO! Sustained improvement of symptoms, QoL & stable THV function @ 1Y. @MayoClinicCV

[Manel boumeg.MD @manelboumeg]

Important work 👏 @AbdullahAlabcha

[Abdullah Al-Abcha @AbdullahAlabcha]

Had an incredible time at #TVT2023 🎉 Grateful for the #opportunity to present our work📝 on staging #MAC🫀while catching up on the latest #innovations in #SHD🤩

#CardioTwitter #MedTwitter @crfheart

[Manel boumeg.MD @manelboumeg]

@jbcarmody @mmaturanaMD

[Manel boumeg.MD @manelboumeg]

#HRS2023 #ACCFIT #UofM congrats @JasneetDevgun

[Jasneet Devgun @JasneetDevgun]

⚡️Had the honor of presenting our study on outcomes of endocardial vs epicardial leads in patients w/ tricuspid valve prostheses at #HRS2023! ⚡️
20 years of data showing:

🌟Only mild ⬆️ TR & RV dysfxn w/endocardial lead
🌟 significant ⬆️ epicardial lead thresholds over time

[Europace Editor-in-Chief @EuropaceEiC]

🎯Left Atrial Appendage Closure In Patients With Hypertrophic Cardiomyopathy And Atrial Fibrillation

#EUROPACE_FRESH_OFF_THE_PRESS

⚡️see data from U.S.A. 🇺🇸 NRD now available in #Europace

https://t.co/v113SsKE0N

@GiulioConte9 @marcovitoloMD @AndyZhangMD @FraSantoroMD

[Mohammed Qintar, MD MSc @MohammedQintar]

Pre TEER work up angiogram with a surprise. Super rare anomaly! You have to respect that proximal RCA!! Anybody has data on how common this is?

[Manel boumeg.MD @manelboumeg]

@syamkumarmd @EPeeps_Bot @CHRS_SCR @markmujermd

[Edgardo Alania @Ed_Alania]

🫀 Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis @JACCJournals #CardioEd #Cardiology #Amyloidosis #whycmr

[Manel boumeg.MD @manelboumeg]

Stay tuned for more lectures #AASA

[Taha @merghout]

The lecture series is for anyone interested in understanding the path to residency and licensure in the US medical system.
The webinar that will take place on Saturday, April 1st, 11 AM EDT (US east coast time) which corresponds to 16:00 DZT (Algerian tim…https://t.co/PKfFmCJ9q3

[Akshay Khandelwal MD MBA @KhandelwalMD]

Presentation on #AMICS by @HadleyWilsonMD #JSC2023
- most import device is PA catheter👈🏽
- use shock scores, hemodynamics to assess MCS. Don’t just “fire and forget”
- ensure tissue perfusion/end organ support
- escalate MCS when needed

@JCIRC_IPR @ACCinTouch @DickKovacs

[Manel boumeg.MD @manelboumeg]

@JasneetDevgun This session was amazing !